IF a biaryl-linked benzimidazole small molecule (working designation BBZ-1), designed via structure-guided docking to PDB 8AX9, featuring a benzimidazole core projecting into the Glu109 sub-pocket and a para-substituted biaryl linker locking hydrogen-bond geometry at Arg61/Asp65, is administered at 1–10 µM (in vitro) or 30 mg/kg/day oral gavage (in vivo) to aged (18-month) C57BL/6J mice expressing human APOE4 via knock-in or AAV neuronal delivery,

THEN the following measurable outcomes will be observed:

• FRET-based APOE4 domain interaction IC50 <50 nM (compared to 23–116 nM for phthalazinone lead compounds)
• SPR binding to recombinant APOE4 N-terminal domain: Kd <100 nM
• Thermal shift assay: ΔTm >3°C vs. DMSO vehicle in APOE4, with <0.5°C shift in APOE3 confirming isoform selectivity
• >20-fold selectivity over APOE3 in FRET domain interaction assay
• In APOE4 knock-in neurons: ≥40% reduction in secreted Aβ42:Aβ40 ratio, ≥30% improvement in mitochondrial membrane potential (JC-1 assay), and ≥25% increase in lipidated APOE particle size by native PAGE
• In aged APOE4 mice: ≥20% reduction in insoluble hippocampal Aβ42 burden by ELISA, and restoration of dendritic spine density toward APOE3 knock-in reference levels

BECAUSE the following causal chain is operative:

1. The Arg61-Glu255 salt bridge is the structural lesion driving APOE4 pathology. In APOE4, Arg112 repels Arg61 out of the helix bundle, enabling Arg61 to form a pathological intramolecular salt bridge with Glu255 in the C-terminal domain; this "domain interaction" locks APOE4 into a compact, dysfunctional conformation distinct from APOE3, impairing lipidation and receptor binding (structural pathology review)[https://pmc.ncbi.nlm.nih.gov/articles/PMC1222763/].

2. Breaking this salt bridge via small molecule binding to the N-terminal domain restores APOE3-like open conformation. Prior structure correctors (phthalazinone derivatives) demonstrated that competitive occupancy of the Arg61 region disrupts the Arg61-Glu255 interaction, measurable by FRET between N- and C-terminal fluorescent tags, achieving 23–116 nM IC50 and rescuing neuronal phenotypes—proving the mechanism is pharmacologically tractable (phthalazinone series, Chen et al. J Biol Chem 2012, PMID 22267727)[https://pmc.ncbi.nlm.nih.gov/articles/PMC1222763/].

3. Natural compound correctors (e.g., PHC) validated the binding site but failed due to conformational instability. Villareal et al. (2013) showed via high-throughput screening and MD simulations that PHC binds the APOE4 N-terminal domain and transiently disrupts domain interaction; however, MD trajectories revealed loss of binding geometry over simulation time, attributed to insufficient rigidity of the scaffold and lack of secondary anchor contacts—establishing the precise pharmacophoric failure mode that BBZ-1 must correct (Villareal et al., natural correctors with MD instability)[https://pmc.ncbi.nlm.nih.gov/arti...

SENS category: LysoSENS